Annual Drug Patent Expirations for XTANDI
Xtandi is a drug marketed by Astellas and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for XTANDI.
This drug has one hundred and twenty-nine patent family members in twenty-eight countries.
The generic ingredient in XTANDI is enzalutamide. One supplier is listed for this compound. Additional details are available on the enzalutamide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
